Table of Contents
- Introduction: Why the GABAergic Mechanism Matters
- What Is GABA and Why Does It Matter for Anxiety and Sleep?
- The 2010 Landmark Study: Direct GABA_A Currents in Hippocampal Neurons
- The 2011 Mechanistic Study: Uptake Inhibition and Receptor Binding
- The 2024 Rat Study: GABAergic Inhibition and Dopamine Interactions
- Passiflora Incarnata Flavonoids: Apigenin, Chrysin, and GABA_A Partial Agonism
- GABA_A vs. GABA_B: Which Receptor Does Passionflower Target?
- Passionflower vs. Benzodiazepines: A Safer Anxiolytic Alternative?
- Passionflower Clinical Study Anxiety Data: What Human Trials Show
- Passionflower Sleep Research: GABA, Sedation, and Cortisol
- How Extraction Method Changes Everything
- Frequently Asked Questions
- Conclusion: What the Evidence Tells Us
Introduction: Why the GABAergic Mechanism Matters
If you've spent any time researching natural anxiolytics, you've almost certainly encountered Passiflora incarnata — the purple-flowered vine native to the southeastern United States that has been used as a calming botanical for centuries. But in the last fifteen years, researchers have moved well beyond folk medicine and into serious molecular pharmacology, asking a specific and mechanistically important question: how, exactly, does this plant calm the nervous system?
The answer, as the evidence increasingly shows, runs directly through the GABAergic system — the same neurotransmitter pathway targeted by benzodiazepines, barbiturates, and alcohol. Understanding the Passiflora incarnata GABAergic mechanism is not merely an academic exercise. It tells us whether the plant works via the same receptor targets as pharmaceutical anxiolytics, whether it carries similar risks, whether it can be dosed rationally, and whether it deserves serious clinical consideration rather than polite dismissal.
This post synthesizes the most important passionflower GABA study data published to date — including a 2024 rat study that adds new dimensions to our understanding — and answers the questions that practitioners, researchers, and educated consumers are actually asking.
Support Your Stress Response, Lower Cortisol and Feel Calmer, Clearer and More Like Yourself Again.
Try our new organic cortisol balance drops risk free
Shop Organic Cortisol Balance Drops
What Is GABA and Why Does It Matter for Anxiety and Sleep?
Before diving into the specific passiflora incarnata research, it helps to understand why GABAergic pharmacology is so central to the conversation about anxiety and sleep in the first place.
GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the mammalian central nervous system. It works by binding to specific receptors — primarily GABA_A and GABA_B — and reducing neuronal excitability. When GABAergic tone is high, the nervous system quiets down. When it is low or disrupted, anxiety, hyperarousal, insomnia, and even seizures can result.
- GABA_A receptors are ionotropic receptors (ligand-gated ion channels). When activated, they allow chloride ions to enter the neuron, hyperpolarizing it and reducing its likelihood of firing. Benzodiazepines work by positively modulating GABA_A receptors — they don't activate the receptor directly, but they make it more sensitive to GABA itself.
- GABA_B receptors are metabotropic receptors (G-protein coupled). They regulate presynaptic neurotransmitter release and have somewhat different physiological roles, including modulation of pain, muscle tone, and certain forms of anxiety and addiction.
The distinction between these two receptor types turns out to be critically important when interpreting the passionflower GABAergic research, because different studies suggest P. incarnata may interact with each receptor class in different ways.
The 2010 Landmark Study: Direct GABA_A Currents in Hippocampal Neurons
One of the most cited pieces of evidence in the passionflower GABA study literature comes from a 2010 investigation examining the direct electrophysiological effects of whole P. incarnata extract on rat brain tissue.
What researchers did: They applied whole Passiflora incarnata extract to rat hippocampal CA1 neurons in vitro and measured GABA_A receptor currents using patch-clamp electrophysiology.
What they found: The extract induced dose-dependent direct GABA_A currents — meaning it was capable of activating the receptor directly, not merely modulating it the way benzodiazepines do. This is a pharmacologically significant distinction. The extract did not modulate synaptic GABA_A currents (the naturally occurring ones driven by endogenous GABA), which suggests a partial or selective agonism rather than a broad potentiating effect.
The GABA content angle: When the researchers tested 21 plants for GABA content, Passiflora incarnata came back with notably high GABA levels — raising the intriguing possibility that the plant's GABA content itself may contribute to the observed receptor activation, rather than (or in addition to) secondary metabolites like flavonoids.
This study, published in PLOS ONE and available via PubMed Central, fundamentally shaped subsequent passiflora and GABAa receptors research by demonstrating that whole extract could produce direct receptor activation, something not previously well-documented in a rigorous electrophysiological framework.
Key takeaway: Whole P. incarnata extract can directly activate GABA_A receptors in hippocampal neurons in a dose-dependent manner. The plant's high endogenous GABA content may contribute to this effect.
The 2011 Mechanistic Study: Uptake Inhibition and Receptor Binding
Where the 2010 study focused on electrophysiology, the 2011 investigation — cited extensively on Semantic Scholar — took a more comprehensive biochemical approach to the passiflora anxiolytic mechanism, examining multiple points in the GABAergic pathway simultaneously.
The experimental design: Researchers used a dry extract of Passiflora incarnata and tested it against three key mechanisms:
- GABA uptake into rat cortical synaptosomes (using radiolabeled [³H]-GABA)
- GABA release from synaptosomes
- GABA transaminase activity (the enzyme that breaks down GABA)
They also performed radioligand binding assays with:
- [³H]-SR95531 (a GABA_A antagonist) to assess GABA_A receptor binding
- [³H]-CGP 54626 (a GABA_B antagonist) to assess GABA_B receptor binding
- [³⁵S]-GTPγS functional assay to characterize receptor activity at GABA_B
What they found:
The dry extract inhibited [³H]-GABA uptake into rat cortical synaptosomes in a concentration-dependent manner. This is significant: if the plant reduces the reuptake of GABA, more GABA remains available at the synapse, prolonging and amplifying inhibitory neurotransmission — a mechanism conceptually similar to how SSRIs work for serotonin.
However — and this is important — the extract showed no significant effect on GABA release and no effect on GABA transaminase activity. So the mechanism is specifically about uptake, not production or breakdown.
On the receptor binding side, the extract showed concentration-dependent inhibition of binding at both GABA_A and GABA_B receptors, indicating direct interaction with receptor binding sites.
The [³⁵S]-GTPγS assay then classified the extract as a GABA_B antagonist — meaning at GABA_B receptors, the extract appears to block rather than activate the receptor. This is a nuanced and somewhat counterintuitive finding that has significant implications for understanding the full spectrum of passionflower's GABAergic pharmacology.
Key takeaway: P. incarnata dry extract inhibits GABA reuptake (increasing synaptic GABA availability), binds to both GABA_A and GABA_B receptors, and acts as a GABA_B antagonist. Multiple GABAergic mechanisms are likely operating simultaneously.
Support Your Stress Response, Lower Cortisol and Feel Calmer, Clearer and More Like Yourself Again.
Try our new organic cortisol balance drops risk free
Shop Organic Cortisol Balance DropsThe 2024 Rat Study: GABAergic Inhibition and Dopamine Interactions
The most recent high-quality passiflora incarnata research to examine the GABAergic mechanism was published in 2024 in the Journal of Pre-Clinical and Clinical Research (18(1):1–10), titled "Effect of Passiflora incarnata L. extract on exploratory behaviour and neurotransmitters level in the structures involved in motor functions in rats."
This study adds several important new dimensions to the picture.
Behavioral findings: Rats treated with P. incarnata extract showed an inhibitory effect on GABAergic pathway activity, with measurable reductions in exploratory behavior — a standard preclinical marker of sedation or anxiolysis. This behavioral evidence is consistent with increased GABAergic tone (more inhibitory signaling = less exploratory drive).
The dopamine surprise: Perhaps the most unexpected finding was that P. incarnata extract increased spinal dopamine levels in treated rats. This suggests the plant's pharmacological footprint extends beyond pure GABAergic modulation and may involve dopaminergic neurotransmission in spinal motor circuits. The interaction between GABAergic inhibition and dopaminergic activation is complex and not yet fully understood, but it raises important questions about the full therapeutic — and potential adverse effect — profile of the extract.
Mechanistic interpretation: The authors proposed that the sedative and anxiolytic effects of the extract likely arise from a combination of:
- Direct GABA_A and GABA_B receptor affinity
- Reuptake inhibition (consistent with the 2011 findings)
- Flavonoid-mediated partial agonism at GABA_A receptors (discussed in the next section)
Clinical relevance: The authors explicitly discussed the potential for P. incarnata to serve as a benzodiazepine alternative — a significant claim that is examined more carefully later in this post.
Key takeaway: The 2024 study confirms GABAergic inhibition as a central mechanism, introduces dopaminergic modulation as a complicating factor, and provides contemporary behavioral evidence in support of the plant's anxiolytic and sedative properties.
Passiflora Incarnata Flavonoids: Apigenin, Chrysin, and GABA_A Partial Agonism
Any serious discussion of the passiflora incarnata GABAergic mechanism must address the flavonoids — the class of polyphenolic secondary metabolites that represent some of the most pharmacologically active constituents of the plant.
Passiflora incarnata contains a rich array of passiflora incarnata flavonoids, including:
- Apigenin (4',5,7-trihydroxyflavone)
- Chrysin (5,7-dihydroxyflavone)
- Vitexin and isovitexin (C-glycosylflavones)
- Orientin and isoorientin
- Luteolin
Of these, apigenin and chrysin have received the most attention for their GABAergic properties.
Chrysin has been shown to bind to the benzodiazepine site of the GABA_A receptor. It acts as a partial agonist at GABA_A — it can activate the receptor but does so less completely than full agonists like diazepam. This partial agonism is actually considered pharmacologically desirable in the context of anxiolytic development, as it may confer anxiolytic effects with a lower risk of dependence, tolerance, and sedation compared to full benzodiazepines.
Apigenin has demonstrated anxiolytic effects in preclinical models. Studies have shown it binds to central benzodiazepine receptors, though with lower affinity than classical benzodiazepines, and it has been shown to reduce anxiety-related behavior in mice without significant sedation at lower doses.
The 2024 study specifically cited apigenin and chrysin as contributors to the observed GABA_A partial agonism in the extract, reinforcing the view that flavonoid content is a critical determinant of passionflower anxiety evidence and therapeutic potency.
The synergy question: Whether the flavonoids act synergistically with the plant's endogenous GABA content and with each other is an area of ongoing research. The general consensus emerging from the passiflora incarnata research literature is that whole-extract preparations likely produce more robust GABAergic effects than any single isolated constituent — a classic case of botanical synergy.
GABA_A vs. GABA_B: Which Receptor Does Passionflower Target?
Based on the research reviewed above, the honest answer is: both, but in different ways.
The evidence for passiflora and GABAa receptors is strong:
- Whole extract induces direct GABA_A currents in hippocampal neurons (2010)
- Flavonoids (apigenin, chrysin) act as partial GABA_A agonists
- GABA_A receptor binding is inhibited by the extract in a concentration-dependent manner (2011)
- Behavioral evidence of GABA_A-mediated sedation is consistent across multiple studies
The evidence for GABA_B interaction is more complex:
- The 2011 study found concentration-dependent binding at GABA_B receptors
- The [³⁵S]-GTPγS assay classified the extract as a GABA_B antagonist — not an agonist
- GABA_B antagonism could theoretically increase excitatory neurotransmission (since GABA_B activation normally inhibits neurotransmitter release), which seems contradictory to the sedative/anxiolytic profile
- However, the net functional outcome depends on which neuronal populations, brain regions, and circuits are involved
The 2024 study adds further nuance by suggesting that both GABA_A and GABA_B receptor affinity contribute to the extract's sedative properties, alongside dopaminergic effects and reuptake inhibition.
The emerging picture is one of a pharmacologically complex plant that modulates multiple points in the GABAergic system — and likely other neurotransmitter systems — rather than acting via a single clean mechanism. This complexity may actually be an advantage: it could reduce the probability of receptor downregulation and tolerance development compared to drugs that hit a single receptor with high potency.
Passionflower vs. Benzodiazepines: A Safer Anxiolytic Alternative?
This is the question that animates much of the passionflower anxiety evidence research: can P. incarnata serve as a genuine alternative to benzodiazepines?
The passiflora anxiolytic mechanism research provides a basis for cautious optimism, but also important caveats.
Arguments in favor:
- Mechanistic plausibility: The plant genuinely engages GABAergic pathways, so the mechanism for anxiolytic activity is real, not merely speculative.
- Partial agonism may reduce dependence risk: The flavonoids' partial agonism at GABA_A, rather than full agonism like benzodiazepines, theoretically reduces the risk of tolerance and physical dependence — though long-term human studies are needed to confirm this.
- Clinical data: A notable 2001 double-blind randomized controlled trial (Journal of Clinical Pharmacy and Therapeutics) compared P. incarnata extract to oxazepam (a benzodiazepine) in 36 patients with generalized anxiety disorder. The extract performed comparably to oxazepam on anxiety measures, with the significant advantage of causing less impairment of job performance — a clinically meaningful finding from passionflower clinical study anxiety research.
- Safety profile: The 2008 HPLC-characterized extract study demonstrated in vivo GABA-mediated anxiolytic activity in mice with a favorable safety profile, consistent with the relatively benign adverse effect profile seen in human studies.
Arguments for caution:
- The evidence base is still limited: Most of the mechanistic work is preclinical (cell and animal studies). The number of rigorous human RCTs is small.
- Standardization problems: Without standardized extracts, it is difficult to ensure consistent therapeutic doses in commercial products.
- GABA_B antagonism complexity: The GABA_B antagonist classification raises questions about net CNS effects that are not yet fully resolved.
- Drug interactions: Because P. incarnata affects GABAergic tone, there is potential for additive effects with benzodiazepines, alcohol, and other CNS depressants — a clinical consideration that should not be ignored.
Bottom line: For mild-to-moderate anxiety, P. incarnata represents a mechanistically coherent, clinically supported option. It is not a direct benzodiazepine equivalent, but its pharmacology suggests it may offer meaningful anxiolytic effects with a potentially more favorable safety profile for long-term use.
Support Your Stress Response, Lower Cortisol and Feel Calmer, Clearer and More Like Yourself Again.
Try our new organic cortisol balance drops risk free
Shop Organic Cortisol Balance DropsPassionflower Clinical Study Anxiety Data: What Human Trials Show
Beyond the mechanistic preclinical work, what does the passionflower clinical study anxiety literature actually show in human subjects?
2001 RCT vs. Oxazepam: As noted above, the landmark passionflower GABA study comparison with oxazepam found comparable anxiolytic efficacy with fewer cognitive side effects. This remains one of the most clinically significant studies in the field.
2011 Preoperative Anxiety Trial: A randomized controlled trial published in Phytotherapy Research found that oral P. incarnata extract administered prior to surgery significantly reduced preoperative anxiety compared to placebo, without affecting sedation levels or psychomotor performance. This is important because it separates the anxiolytic effect from the sedative effect — the extract reduced worry and tension without impairing function.
What the human data tells us about mechanism: While human trials don't typically allow direct examination of receptor pharmacology, the clinical pattern — anxiolytic without significant sedation at standard doses, relatively rapid onset, and good tolerability — is consistent with the partial GABA_A agonism model suggested by the preclinical passiflora incarnata research.
Passionflower Sleep Research: GABA, Sedation, and Cortisol
The connection between passionflower and sleep runs through the same GABAergic pathways that mediate its anxiolytic effects. Passionflower sleep research has examined both subjective sleep quality and objective physiological markers.
The GABA-sleep connection: At higher doses, enhanced GABAergic tone promotes sleep onset and maintenance — the same basic mechanism underlying the sedative properties of benzodiazepines and the non-benzodiazepine "Z-drugs" (zolpidem, eszopiclone). The 2024 rat study demonstrated inhibitory effects on exploratory behavior that are consistent with sedation, and proposed GABA_A/B affinity as the mechanistic driver.
Human sleep trial (2011): A crossover study published in Phytotherapy Research found that drinking P. incarnata tea nightly for one week was associated with significantly improved sleep quality scores compared to a placebo tea, as measured by subjective sleep diary ratings. Participants reported improvements in sleep time, sleep efficiency, and waking after sleep onset.
The passiflora cortisol study angle: Cortisol — the primary stress hormone — is intimately connected to both anxiety and sleep disruption. Elevated nighttime cortisol is one of the most consistent biological correlates of insomnia and generalized anxiety. While dedicated passiflora cortisol study research is limited, the biological logic is sound: by enhancing GABAergic inhibition, which broadly reduces CNS arousal, P. incarnata may indirectly reduce hypothalamic-pituitary-adrenal (HPA) axis activation and cortisol output. Animal studies have demonstrated that GABA_A agonism can suppress stress-induced cortisol elevations, and it is reasonable to hypothesize that P. incarnata's GABAergic effects produce similar HPA suppression — though direct human cortisol data remains limited and is an important gap in the literature.
Key takeaway for sleep: The passionflower GABAergic effects on sleep appear to be real, modest in magnitude, and mechanistically consistent with what the preclinical pharmacology predicts. This is not a sedative hypnotic equivalent to prescription sleep medications, but it may offer meaningful support for mild sleep difficulty, particularly anxiety-driven insomnia.
How Extraction Method Changes Everything
One of the most practically important — and frequently overlooked — dimensions of the passiflora incarnata research is how dramatically extraction method affects the pharmacological activity of the resulting preparation.
The whole-extract vs. dry-extract divergence: The 2010 study used whole extract and found direct GABA_A current induction in hippocampal neurons. The 2011 study used dry extract and found GABA uptake inhibition and receptor binding effects, but also classified the preparation as a GABA_B antagonist. These differences may reflect genuine pharmacological differences between preparation types, not merely methodological variation.
Why this matters clinically:
The GABA content of P. incarnata is high compared to other plants, but GABA from oral sources faces significant challenges crossing the blood-brain barrier via conventional routes. Some researchers argue that the plant's GABA may nonetheless contribute to central effects via intestinal GABA receptors and the gut-brain axis, or via as-yet-uncharacterized transport mechanisms.
Flavonoid content varies substantially depending on:
- Plant part used (aerial parts vs. leaves vs. stem)
- Harvest timing and geographical origin
- Solvent system (ethanol, water, methanol, or combinations)
- Concentration and drying methods for standardized extracts
The 2008 HPLC study: A 2008 investigation used HPLC-characterized P. incarnata extract to demonstrate in vivo GABA-mediated anxiolytic activity in mice, establishing that careful chemical characterization of the extract can predict and verify pharmacological activity. This supports the argument that passionflower anxiety evidence is most meaningful when applied to standardized, chemically characterized preparations — not generic "passionflower" preparations that may vary wildly in active constituent content.
Practical implication: When evaluating commercial passiflora incarnata products, look for preparations that specify:
- Standardized flavonoid content (often expressed as total flavonoids or specific compounds like vitexin)
- Extraction ratio (e.g., 5:1 or 10:1)
- The plant part used
- The extraction solvent
Frequently Asked Questions
Q: Does Passiflora incarnata directly activate GABA_A receptors, or does it work by modulating GABA availability?
A: Both mechanisms appear to be operating. The 2010 study showed whole extract induces direct GABA_A currents in hippocampal neurons. The 2011 study showed dry extract inhibits GABA reuptake, increasing synaptic GABA availability. The flavonoids (apigenin, chrysin) act as partial GABA_A agonists via the benzodiazepine binding site. The overall picture involves multiple mechanisms rather than a single pharmacological action.
Q: What flavonoids in P. incarnata are most responsible for its GABAergic effects?
A: Chrysin and apigenin are the best-characterized contributors to GABA_A partial agonism. Both bind to the benzodiazepine recognition site on the GABA_A receptor. Vitexin and isovitexin may contribute additional effects. However, the whole-extract synergy between flavonoids and the plant's intrinsic GABA content likely produces more robust effects than any single isolated compound.
Q: Is passionflower a genuine alternative to benzodiazepines for anxiety?
A: For mild-to-moderate generalized anxiety, the mechanistic and clinical evidence supports P. incarnata as a viable option. A head-to-head clinical trial showed comparable efficacy to oxazepam with fewer cognitive side effects. However, it is not appropriate to position it as equivalent to benzodiazepines for severe anxiety or panic disorder without more robust clinical trial data. The partial agonism mechanism theoretically reduces dependence and tolerance risk — a potential advantage — but long-term human data is lacking.
Q: Does extraction method affect how well passionflower works?
A: Yes, substantially. The 2010 whole-extract study and 2011 dry-extract study showed different mechanistic profiles. Flavonoid content — which varies dramatically with preparation method — directly affects GABA_A partial agonism. HPLC-characterized standardized extracts have demonstrated reliable in vivo anxiolytic activity in research settings. Unstandardized preparations may have unpredictable potency.
Q: Does P. incarnata interact with GABA_B receptors as well as GABA_A?
A: Yes. The 2011 study found concentration-dependent binding at GABA_B receptors and classified the extract as a GABA_B antagonist via functional assay. The 2024 study also cited GABA_B receptor affinity as contributing to observed sedative effects. The functional implications of GABA_B antagonism are complex and not yet fully characterized in the context of P. incarnata's overall pharmacological profile.
Q: Can P. incarnata help with sleep, and is there cortisol evidence?
A: Human sleep studies show modest but statistically significant improvements in subjective sleep quality. The GABAergic mechanism — particularly GABA_A agonism — is consistent with sleep-promoting effects. Direct human passiflora cortisol study data is limited, but the mechanistic pathway from GABAergic enhancement to HPA axis suppression and reduced cortisol is biologically plausible and supported by preclinical evidence.
Support Your Stress Response, Lower Cortisol and Feel Calmer, Clearer and More Like Yourself Again.
Try our new organic cortisol balance drops risk free
Shop Organic Cortisol Balance DropsConclusion: What the Evidence Tells Us
The Passiflora incarnata GABAergic mechanism study literature, taken as a whole, tells a coherent and increasingly well-supported story.
Passiflora incarnata engages the GABAergic system through multiple simultaneous mechanisms: direct GABA_A receptor activation (particularly by whole extract and isolated flavonoids), reuptake inhibition that increases synaptic GABA availability, and binding at both GABA_A and GABA_B receptor sites. The flavonoids — particularly chrysin and apigenin — act as partial GABA_A agonists via the benzodiazepine binding site, providing a mechanistic explanation for anxiolytic effects that parallels, but does not replicate, conventional benzodiazepine pharmacology.
The 2024 rat study adds the important finding that dopaminergic neurotransmission is also affected, with increases in spinal dopamine levels observed alongside GABAergic inhibition. This reminds us that P. incarnata is a pharmacologically complex botanical medicine, not a single-mechanism drug.
From a clinical standpoint, the passionflower clinical study anxiety data — particularly the head-to-head comparison with oxazepam — provides meaningful evidence of efficacy in generalized anxiety, with a safety profile that appears more favorable than benzodiazepines for parameters like cognitive performance. Passionflower sleep research supports modest but genuine improvements in sleep quality, consistent with the GABAergic mechanism.
The key gaps in the evidence base are:
- Larger, better-powered human RCTs with standardized, chemically characterized extracts
- Long-term safety data in humans, particularly regarding tolerance and dependence
- Direct human cortisol studies examining HPA axis modulation
- Mechanistic clarity on the functional implications of GABA_B antagonism
- Bioavailability studies examining how the plant's GABA content and flavonoids actually reach the CNS following oral administration
Despite these gaps, the current body of passionflower GABAergic research justifies serious consideration of P. incarnata as a botanical anxiolytic with a mechanistically plausible, clinically supported, and relatively well-characterized pharmacological basis. The era of dismissing it as "just an herb" is over. The era of treating it as a fully validated pharmaceutical equivalent has not yet arrived. The honest answer lies between those extremes — and the research, pleasingly, continues to sharpen that answer with each new study.
This post is intended for educational purposes and does not constitute medical advice. Consult a qualified healthcare provider before using any botanical supplement, particularly if you are taking medications that affect the central nervous system.
References:
- Appel K, Rose T, et al. (2011). Modulation of the γ-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytotherapy Research. [Semantic Scholar]
- Elsas SM, et al. (2010). Passiflora incarnata L. (Passionflower) extracts elicit GABA currents in hippocampal neurons in vitro, and show anxiogenic and anticonvulsant effects in vivo, varying with extraction method. Phytomedicine. PMC2941540.
- Mikulska P, et al. (2024). Effect of Passiflora incarnata L. extract on exploratory behaviour and neurotransmitters level in the structures involved in motor functions in rats. Journal of Pre-Clinical and Clinical Research, 18(1):1–10.
- Akhondzadeh S, et al. (2001). Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. Journal of Clinical Pharmacy and Therapeutics, 26(5):363–367.
- Ngan A, Conduit R. (2011). A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (passionflower) herbal tea on subjective sleep quality. Phytotherapy Research, 25(8):1153–1159.
0 comments